About GeneCraft
GeneCraft is a Healthcare company based in Cheongju-si (South Korea) founded in 2020. Gene therapies for cancer treatment are developed using AAV vectors. GeneCraft has raised $7.61 million across 1 funding round from investors including Seoul National University and InfoBank. Its focus areas include Life Sciences, Oncology, Drugs and Lung Cancer. Its competitors include Bridge Biotherapeutics and Daan Biotherapeutics; 2 of its 2 listed competitors have raised funding.
Company details
GeneCraft was founded in 2020 and is based in Cheongju-si, South Korea. Focus is placed on the biotechnology sector, where gene therapies for cancer treatment are developed. Custom production of genes of interest is enabled through AAV vectors. Operations include the creation of therapies such as RX001, targeted at lung cancer. The companys activities center on advancing these therapeutic approaches for oncology applications.
- Headquarters Cheongju-si, South Korea
- SectorsHealthcare
- Website genecraft.co.kr
- Social LinkedIn
- Total Equity Funding$7.61M (USD)
in 1 rounds
- Latest Funding Round$7.61M (USD), Series A
Jan 2024
- InvestorsSeoul National University
& 1 more
Funding Insights of GeneCraft
GeneCraft has successfully raised a total of $7.61M through 1 strategic funding round. The most recent funding activity was a Series A round of $7.61 million completed in January 2024. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $7.61M
- Total Rounds 1
- Last Round Series A — $7.61M
- First Round $7.61M
(Jan 2024)
- Investors Count 2
All 1 funding rounds of GeneCraft with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jan 2024 | $7.61M | Series A | – | – |
2 investors in total: 2 institutional.
Investors in GeneCraft
GeneCraft has secured backing from 2 investors, including institutional investors. Prominent investors backing the company include Seoul National University and InfoBank.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Multiple courses and degrees are offered across diversified academic streams. | 1946 | snu.ac.kr | Seoul, South Korea | |
IT service suite solutions are provided for various business needs. | 1995 | infobank.net | Seongnam-si, South Korea |
Investor details for GeneCraft
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
Timeline of GeneCraft
2 dated milestones of GeneCraft across 4 years, from founding to its latest funding, stage changes and deals.
- Founded GeneCraft is founded.
- Funding First funding round of $7.6M.
Competitors of GeneCraft
GeneCraft has 2 listed competitors in our database, 2 of them funded. They include Bridge Biotherapeutics and Daan Biotherapeutics.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| bridgebiorx.com | 2015 | Seongnam-si, South Korea | $10M | 6 | Small molecule therapeutics are developed for treating various diseases. | |
| daanbiotpx.com | 2020 | Seoul, South Korea | $17.21M | Therapeutics for cancer treatment are developed using immune-based cell therapies. |
Detailed competitors of GeneCraft
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Genecraft
Complete news archive for GeneCraft
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about GeneCraft
GeneCraft was founded in 2020 and raised its 1st funding round 4 years after it was founded.
GeneCraft is headquartered in Cheongju-si, South Korea. It is registered at Cheongju-si, North Chungcheong, South Korea.
GeneCraft is a funded company, having raised a total of $7.61M across 1 funding round to date. The company's 1st funding round was a Series A of $7.61M, raised on Jan 2024.
GeneCraft was founded in 2020 and is based in Cheongju-si, South Korea. Focus is placed on the biotechnology sector, where gene therapies for cancer treatment are developed. Custom production of genes of interest is enabled through AAV vectors. Operations include the creation of therapies such as RX001, targeted at lung cancer. The companys activities center on advancing these therapeutic approaches for oncology applications.
GeneCraft's top competitors include Bridge Biotherapeutics and Daan Biotherapeutics.
GeneCraft has 2 investors. Key investors include Seoul National University, and InfoBank.